Sirolimus

Discovery and origin

Sirolimus has one of the most unusual discovery stories in pharmacology. Initially, this biologically active substance was isolated during microbiological studies of soil samples brought back from an expedition to the famous Easter Island, which the indigenous people call Rapa Nui. This geographical origin gave the molecule its second, historical and widely known name in scientific literature — rapamycin. Soil bacteria belonging to the species Streptomyces hygroscopicus turned out to be the direct producers of this unique compound.

Mechanism of action: focus on mTOR

To deeply understand the pharmacodynamics of sirolimus, it is necessary to examine its intracellular targets in detail and compare them with the action of classic calcineurin inhibitors.

At the first stage, the sirolimus molecule penetrates inside the T-lymphocyte. There, it finds its specific receptor — the binding protein FKBP-12. It is important to note that another potent immunosuppressant, tacrolimus, binds to this exact same intracellular protein.

However, this is where the similarity ends, and the subsequent intracellular cascade of reactions differs drastically. The resulting «sirolimus + FKBP-12» complex has no effect on calcineurin. Its specific and sole target becomes the mTOR protein (short for mammalian target of rapamycin).

Under normal physiological conditions, the mTOR protein acts as a crucial intracellular regulator. It controls the progression of the T-lymphocyte through the cell cycle, specifically responsible for the successful transition of the cell from the initial growth and preparation phase (G1 phase) to the DNA synthesis phase (S phase). By blocking mTOR activity, sirolimus causes an insurmountable cell cycle arrest. Consequently, the proliferation (active division) of T-lymphocytes is completely halted, which provides the immunosuppressive effect.

Relation to interleukin-2 (IL-2)

Another fundamental difference between sirolimus and calcineurin inhibitors (such as cyclosporine or tacrolimus) lies in its interaction with interleukin-2 (IL-2).

Calcineurin inhibitors suppress the production of IL-2 itself. Sirolimus implements a completely different strategy: it does not reduce IL-2 production by immune system cells. Instead, the drug blocks the cellular response to this cytokine. In other words, T-lymphocytes lose sensitivity to the stimulating effect of IL-2. Even if interleukin-2 is present in the environment, the cell cannot perceive this signal and does not enter the division process.

Pharmacokinetics and clinical tactics

From a pharmacokinetic perspective, sirolimus is administered orally. To maintain the necessary therapeutic effect, taking the medication just once a day is sufficient. In the body, sirolimus undergoes metabolism, acting as a substrate for the CYP3A4 isoenzyme. This dictates the need for a rigorous assessment of drug-drug interactions when prescribing concomitant therapy.

In clinical practice, sirolimus is often used as part of combination therapy. It is prescribed together with cyclosporine or tacrolimus. The main goal of this combination is reducing the dose of toxic drugs. This makes it possible to maintain reliable immunosuppression while using lower dosages of each component.

The use of sirolimus requires mandatory therapeutic drug monitoring. Physicians need to regularly measure the concentration of the drug in the patient's blood. This strict control is especially critical in kidney transplantation to prevent graft rejection and minimize risks.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• The role of the CYP3A4 isoenzyme in drug metabolism and drug-drug interactions.
• Cell cycle phases (G1 and S) and the molecular mechanisms of their regulation.
• Therapeutic drug monitoring (TDM) in transplantology: goals and methods.
• Comparative pharmacodynamics of calcineurin inhibitors and mTOR inhibitors.

Other topics in the section "Agents Regulating Immune Processes"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.